Emerging drugs for small cell lung cancer – an update

Bibliography

• Metro G, Cappuzzo F. Emerging drugs for small-cell lung cancer. Expert Opin Emerg Drugs 2009;14:591-606
   PubMed Web of Science ®Google Scholar
• Rossi A, Di Maio M, Chiodini P, COCIS individual patient data (IPD) meta-analysis: carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC) [abstract]. J Clin Oncol 2011;29(Suppl):7022
   Google Scholar
• Goldstein SD, Yang SC. Role of surgery in small cell lung cancer. Surg Oncol Clin N Am 2011;20:769-77
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Ciuleanu TE, Tsekov H, Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Samarzja M, Demidchil Y, Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy [abstract]. J Clin Oncol 2010;28(Suppl):7002
   Google Scholar
• Tang CH, Parham C, Shocron E, Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother Pharmacol 2011;67:1389-400
   PubMed Web of Science ®Google Scholar
• Kimura T, Kudoh S, Hirata K. Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride. Clin Med Insight Oncol 2011;5:23-34
   PubMedGoogle Scholar
• Ettinger DS, Jotte R, Lorigan P, Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:2598-603
   PubMedGoogle Scholar
• Jotte R, Conkling P, Reynolds C, Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011;29:287-93
   PubMed Web of Science ®Google Scholar
• Jotte R, Von Pawel J, Spigel DR, Randomized phase III trial of amrubicin versus topotecan (topo) as second-line treatment for small cell lung cancer (SCLC) [abstract]. J Clin Oncol 2011;29(Suppl):7000
   Google Scholar
• O'Brien ME, Konopa K, Lorigan P, Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. Eur J Cancer 2011;47:2322-30
   PubMed Web of Science ®Google Scholar
• Rossi A, Garassino MC, Cinquini M, Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010;70:119-28
   PubMed Web of Science ®Google Scholar
• Horn L, Dahlberg SE, Sandler AB, Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6006-11
   PubMed Web of Science ®Google Scholar
• Spigel DR, Greco FA, Zubkus JD, Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009;4:1555-60
   PubMed Web of Science ®Google Scholar
• Ready NE, Dudek AZ, Pang HH, Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study. J Clin Oncol 2011;29:4436-41
   Google Scholar
• Spigel DR, Hainsworth JD, Yardley DA, Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-8
   PubMed Web of Science ®Google Scholar
• Spigel DR, Townley PM, Waterhouse DM, Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29:2215-22
   PubMed Web of Science ®Google Scholar
• Bevacizumab in Extensive Small Cell Lung Cancer. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00930891 [Last accessed 1 November 2011]
   Google Scholar
• Dean EJ, Cummings J, Roulston A, Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia 2011;13:339-47
   PubMed Web of Science ®Google Scholar
• Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008;8:121-32
   PubMed Web of Science ®Google Scholar
• Langer CJ, Albert I, Kovacs P, A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC) [abstract]. J Clin Oncol 2011;29:7001
   Google Scholar
• Pore MM, Hiltermann TJ, Kruyt FA. Targeting apoptosis pathways in lung cancer. Cancer Lett 2010; In press
   PubMedGoogle Scholar
• Hubaux R, Vandermeers F, Crisanti MC, Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur J Cancer 2010;46:1724-34
   PubMed Web of Science ®Google Scholar
• Kaminskyy VO, Surova OV, Vaculova A, Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011;32:1450-8
   Google Scholar
• Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011;11:493-501
   PubMed Web of Science ®Google Scholar
• Edwards DK, Allen KE, Arora S, Mechanism for Gli1-induced resistance to combination cisplatin and etoposide in small-cell lung cancer [abstract]. Undergraduate Research Poster Symposium; 2011
   Google Scholar
• Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00887159 [Last accessed 1 November 2011]
   Google Scholar
• A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00927875 [Last accessed 1 November 2011]
   Google Scholar
• Olejniczak ET, Van Sant C, Anderson MG, Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res 2007;5:331-9
   PubMed Web of Science ®Google Scholar
• Tahir SK, Wass J, Joseph MK, Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther 2010;9:545-57
   PubMed Web of Science ®Google Scholar
• Jones MH, Virtanen C, Honjoh D, Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004;363:775-81
   PubMed Web of Science ®Google Scholar
• Ranade AR, Cherba D, Sridhar S, MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol 2010;5:1273-8
   PubMed Web of Science ®Google Scholar
• von Pawel J, Schiller JH, Shepherd FA, Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67
   PubMed Web of Science ®Google Scholar